65,437 trials
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over 2 Weeks — -0.24; -0.37; -0.47 Units on a Scale
Perennial Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale
Hepatitis C, Chronic
Primary: Participants With Treatment Success — 117; 63; 4; 0 Participants
Head and Neck Cancer · Stroke
Primary: Reliability Ratings Among Clinicians Using Real-time Internet Evaluation of Swallowing. — 60 percent agreement
Radius Fractures
Primary: The Grip Strength — 98.3; 62.6 Percentage of opposite side — p=<0.05
Pulmonary Cancer
Primary: Percentage of Participants Who Had an Objective Response Rate(ORR) Based on Response Evaluation Criteria In Solid Tumors (RECIST) Criteria. — 0 Percent of Participants
Multiple Myeloma
Primary: Percent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction — 51; 44 percentage of participants
Fetal Growth Retardation
Primary: Percentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months — 86.0; 14.0 percentage of participants
Haemorrhage · Haemostasis · Cardiovascular Surgery
Primary: Proportion of Subjects Achieving Haemostasis at 3 Minutes — 0.746; 0.333 Proportion of Subjects — p=<0.0001
Gram-Negative Bacterial Infections · Sepsis
Primary: Number of Participants Not Requiring Renal Replacement Therapy (RRT) — 3; 1 participants
Vaccines, Pneumococcal Conjugate Vaccine
Primary: Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2…
Lupus Nephritis
Primary: Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs — 0; 0; 0; 0 Participants
Hereditary Angioedema
Primary: Number of Hereditary Angioedema (HAE) Attacks During Each Prophylactic Therapy Period — 6.1; 12.7; 6.3; 12.7 attacks — p=<0.0001
Dysfunctional Hemodialysis Catheters
Primary: Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 — 21.6; 5.3 percentage of success — p=0.0044
Rheumatoid Arthritis
Primary: Methotrexate Maximum Plasma Concentration — 215; 177 ng/mL